ARTICLE | Company News
London Health Sciences Centre, Novare deal
October 13, 2014 7:00 AM UTC
London Health Sciences Centre granted newco Novare rights to therapeutic products that modulate the hyaluronan-mediated motility receptor ( RHAMM; CD168). RHAMM regulates stem cell production and cell movement. Novare said potential therapeutic applications of RHAMM modulators include arthritis, bronchopulmonary dysplasia (BPD) in premature infants, idiopathic pulmonary fibrosis (IPF) and keloid scars. ...